---
title: "Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Humanistic burden and health-related quality of life"
description: "Formulary evidence on Darovasertib (IDE196, LXS196) in First-line metastatic uveal melanoma, in combination with crizotinib: Humanistic burden and health-related quality of life. Topics: EORTC QLQ-C30 global health status and EQ-5D visual analogue scale in the IMCgp100-202 tebentafusp trial, intent-to-treat analysis set; Health-related quality of life in a randomized phase 2 trial of selumetinib versus chemotherapy; Emotional impacts and treatment burden reported in qualitative interviews; Anxiety before and after surveillance and response scans; 3 further topics. 7 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description/humanistic-burden-and-health-related-quality-of-life"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Humanistic burden and health-related quality of life

<a id="heading-2.2.1.8.1"></a>

## 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

### EORTC QLQ-C30 global health status and EQ-5D visual analogue scale in the IMCgp100-202 tebentafusp trial, intent-to-treat analysis set

> “Global health status and quality of life was assessed using the EORTC QLQ-C30 questionnaire.”
> “EORTC QLQ-C30 was assessed at baseline (Cycle 1 Day 1) and on Day 1 of every other cycle to Cycle 5 Day 1, every fourth cycle thereafter, beginning with Cycle 9 Day 1 and End of Treatment (EOT), up to 36 months. Each cycle is 21 days.”
> “The EQ-5D VAS score records the participant's self-rated health on a vertical visual analogue scale, with 0 being the worst imaginable health state and 100 being the best imaginable health state.”
> “The Intent-to-treat (ITT) Analysis Set comprises all participants assigned to treatment analyzed by the treatment assignment whether or not the participant received the assigned treatment.”

Source: [ClinicalTrials.gov NCT03070392 API record](https://clinicaltrials.gov/api/v2/studies/NCT03070392)

| EORTC QLQ-C30 global health status (score 0 to 100) | Tebentafusp: participants assessed | Tebentafusp: mean | Tebentafusp: SD | Investigator's choice: participants assessed | Investigator's choice: mean | Investigator's choice: SD |
| --- | --- | --- | --- | --- | --- | --- |
| Baseline (cycle 1) | “173” | “76.108” | “20.233” | “65” | “74.872” | “20.439” |
| Change from baseline at cycle 3 | “105” | “0.952” | “16.274” | “35” | “-0.238” | “14.919” |
| Change from baseline at cycle 5 | “94” | “-1.152” | “20.797” | “22” | “-10.227” | “22.557” |
| Change from baseline at cycle 9 | “57” | “-2.193” | “19.577” | “13” | “-8.333” | “13.176” |
| Change from baseline at end of treatment | “76” | “-10.417” | “20.911” | “34” | “-10.539” | “23.148” |

Source: [ClinicalTrials.gov NCT03070392 API record](https://clinicaltrials.gov/api/v2/studies/NCT03070392)

| EQ-5D visual analogue scale (score 0 to 100) | Tebentafusp: participants assessed | Tebentafusp: mean | Tebentafusp: SD | Investigator's choice: participants assessed | Investigator's choice: mean | Investigator's choice: SD |
| --- | --- | --- | --- | --- | --- | --- |
| Baseline (cycle 1) | “194” | “81.0” | “16.36” | “78” | “80.4” | “18.31” |
| Change from baseline at cycle 3 | “136” | “0.4” | “14.69” | “45” | “-0.8” | “14.28” |
| Change from baseline at cycle 5 | “108” | “0.6” | “15.61” | “28” | “-0.7” | “14.38” |
| Change from baseline at cycle 9 | “71” | “-0.9” | “19.81” | “14” | “-3.3” | “13.30” |
| Change from baseline at end of treatment | “95” | “-10.1” | “22.53” | “45” | “-11.7” | “21.40” |

Source: [ClinicalTrials.gov NCT03070392 API record](https://clinicaltrials.gov/api/v2/studies/NCT03070392)

<a id="topic-2.2.1.8.1-2"></a>

### Health-related quality of life in a randomized phase 2 trial of selumetinib versus chemotherapy

> “Data from a phase II trial (clinicaltrials.gov identifier: NCT01143402) where patients with metastatic uveal melanoma were randomized to receive selumetinib, an oral MEK inhibitor, or chemotherapy were analyzed. Patients reported HRQoL at baseline, after 1 month, and end of treatment (n = 118), whereas physicians adjudicated AEs via CTCAE.”
> “Mean HRQoL scores did not significantly differ at each of the three time points.”

Source: [Atkinson et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5303646/)

<a id="topic-2.2.1.8.1-3"></a>

### Emotional impacts and treatment burden reported in qualitative interviews

> “Seventeen patients and 16 clinicians participated in the study. All patients were on anti-cancer treatment at the time of being interviewed, except for three who were deliberating treatment options.”
> “Most patients placed greater emphasis on the emotional, rather than physical, impacts of disease and treatment. Emotional concerns were centred on the existential threat posed by metastatic disease within the context of uncertainty about treatment access and effectiveness. More variably, patients were concerned with burden from treatment in the form of time commitment, travel, need for hospitalisation, and expense. Of the treatments received, immunotherapy – especially tebentafusp – conferred the heaviest inconvenience and symptom burden.”
> “Role functioning/well-being was impacted by symptoms and treatment burden, with several patients reducing or ceasing employment or more physically demanding leisure activities.”

Source: [Ng et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11045555/)

<a id="topic-2.2.1.8.1-4"></a>

### Anxiety before and after surveillance and response scans

> “Fear of disease progression was most often manifest as a preoccupation with investigative tests as an indicator of treatment efficacy and the need to seek alternatives. Feelings of anxiety increased from a few days leading up to a test to when results were received. Patients’ experience of time waiting for results varied from 1 day to 3 weeks, depending on whether they needed to schedule an appointment.”

Source: [Ng et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11045555/)

> “Most participants were able to maintain everyday normalcy but struggled to discuss their illness and treatment with family and friends. Participants reported heightened anxiety in the lead-up to routine scans and while awaiting results.”

Source: [Luckett et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12105258/)

<a id="topic-2.2.1.8.1-5"></a>

### Distress trajectories and worry about recurrence in uveal melanoma survivors

> “In a closed cohort study, we used growth mixture modeling (GMM) to identify statistically optimal trajectories over 6-, 12-, 24-, 36-, 48-, 60-, 72-, and 84-month time point posttreatment in 475 patients.”
> “The majority scored consistently low, but 17.5% showed consistently elevated anxiety, 10.9% consistently elevated depression, and 19.4% consistently elevated FCR.”

Source: [Brown et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36848060/)

> “Non-randomized 5-year study of a consecutive series of 708 UM survivors (51.6% male, mean age 69.03, SD=12.12) with observations at 6, 12, 24, 36, 48 and 60 months.”
> “Generally, no prognostic groups reported anxiety, depression and WREC or QoL scores that exceeded general population norms.”

Source: [Brown et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8964647/)

<a id="topic-2.2.1.8.1-6"></a>

### Quality of life after melphalan percutaneous hepatic perfusion

> “Twenty-four patients (14 males; median age 63.0 years) completed 96 questionnaires. Most scores on all scales declined on day 2/3 after M-PHP. On day 21 after M-PHP, 12 out of 15 scores returned to baseline, including median GHS scores.”
> “Three variables were significantly worse on day 21 compared to baseline: fatigue (6–33; p = 0.002), physical functioning (100 vs 86.7; p = 0.003), and role functioning (100 vs 66.7; p = 0.001).”

Source: [Tong et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11164794/)

> “Retrospective analysis of the change in QoL using the Functional Assessment of Cancer Therapy-General (FACT-G) with mUM patients receiving M-PHP (n = 20).”
> “Baseline FACT-G median (IQR) scores were 101.8 (21.8). QoL scoring significantly decreased immediately after the procedure [day 1; 85 (27.5); P = 0.002] and gradually improved over time. By day 28, QoL almost returned to pre-procedure levels [100.3 (13.8); P = 0.31].”

Source: [Vigneswaran et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10906212/)

<a id="topic-2.2.1.8.1-7"></a>

### EQ-5D-3L health status and health utility after isolated hepatic perfusion, SCANDIUM trial

> “HRQOL was measured by the EuroQol 5-domains 3-levels (EQ-5D-3L) questionnaire over 12 months.”
> “Throughout the 12-month follow-up period, the VAS scores remained stable in the IHP group but there was a decrease in the control group at 6 months (83 vs. 64, P=0.002) and 12 months (86 vs. 63), P=0.002) (Fig. 4A).”
> “There were similar findings for health utility as measured by EQ-5D-3L, with a significant difference between IHP and controls at 6 months (0.87 vs. 0.70, P=0.019) and 12 months (0.88 vs. 0.66, P=0.005) (Fig. 4B). However, this difference was not significant when adjusting for baseline health utility scores with a mean change from baseline at 6 months of −0.02 versus −0.10 (P=0.36) and at 12 months −0.02 versus −0.08 (P=0.49).”

Source: [Olofsson Bagge et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12140551/)

Additional sources: [Campbell et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41807618/)

## Related pages
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Terms and abbreviations](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations.md)
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Product information and disease description](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Clinical evidence](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Economic information and modeling report](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: References](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references.md)
